These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 31832926)

  • 1. Premature Fecal Immunochemical Testing in British Columbia Canada: a Retrospective Review of Physician and Screening Participant Characteristics.
    Sanders D; Bakos B; Gentile L; Telford JJ
    J Gen Intern Med; 2020 Feb; 35(2):444-448. PubMed ID: 31832926
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interval Colorectal Cancer Incidence Among Subjects Undergoing Multiple Rounds of Fecal Immunochemical Testing.
    van der Vlugt M; Grobbee EJ; Bossuyt PMM; Bos A; Bongers E; Spijker W; Kuipers EJ; Lansdorp-Vogelaar I; Spaander MCW; Dekker E
    Gastroenterology; 2017 Aug; 153(2):439-447.e2. PubMed ID: 28483499
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fecal Immunochemical Test Screening and Risk of Colorectal Cancer Death.
    Doubeni CA; Corley DA; Jensen CD; Levin TR; Ghai NR; Cannavale K; Zhao WK; Selby K; Buckner-Petty S; Zauber AG; Fletcher RH; Weiss NS; Schottinger JE
    JAMA Netw Open; 2024 Jul; 7(7):e2423671. PubMed ID: 39028667
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low Rate of Cancer Detection by Colonoscopy in Asymptomatic, Average-Risk Subjects with Negative Results From Fecal Immunochemical Tests.
    Longstreth GF; Anderson DS; Zisook DS; Shi JM; Lin JC
    Clin Gastroenterol Hepatol; 2020 Dec; 18(13):2929-2936.e1. PubMed ID: 32007541
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Participant-Related Risk Factors for False-Positive and False-Negative Fecal Immunochemical Tests in Colorectal Cancer Screening: Systematic Review and Meta-Analysis.
    de Klerk CM; Vendrig LM; Bossuyt PM; Dekker E
    Am J Gastroenterol; 2018 Dec; 113(12):1778-1787. PubMed ID: 30158713
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidence of Interval Colorectal Cancer After Negative Results From First-Round Fecal Immunochemical Screening Tests, by Cutoff Value and Participant Sex and Age.
    Toes-Zoutendijk E; Kooyker AI; Dekker E; Spaander MCW; Opstal-van Winden AWJ; Ramakers C; Buskermolen M; van Vuuren AJ; Kuipers EJ; van Kemenade FJ; Velthuysen MF; Thomeer MGJ; van Veldhuizen H; van Ballegooijen M; Nagtegaal ID; de Koning HJ; van Leerdam ME; Lansdorp-Vogelaar I;
    Clin Gastroenterol Hepatol; 2020 Jun; 18(7):1493-1500. PubMed ID: 31442598
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Guaiac-based faecal occult blood tests versus faecal immunochemical tests for colorectal cancer screening in average-risk individuals.
    Grobbee EJ; Wisse PHA; Schreuders EH; van Roon A; van Dam L; Zauber AG; Lansdorp-Vogelaar I; Bramer W; Berhane S; Deeks JJ; Steyerberg EW; van Leerdam ME; Spaander MC; Kuipers EJ
    Cochrane Database Syst Rev; 2022 Jun; 6(6):CD009276. PubMed ID: 35665911
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Faecal immunochemical tests versus colonoscopy for post-polypectomy surveillance: an accuracy, acceptability and economic study.
    Atkin W; Cross AJ; Kralj-Hans I; MacRae E; Piggott C; Pearson S; Wooldrage K; Brown J; Lucas F; Prendergast A; Marchevsky N; Patel B; Pack K; Howe R; Skrobanski H; Kerrison R; Swart N; Snowball J; Duffy SW; Morris S; von Wagner C; Halloran S
    Health Technol Assess; 2019 Jan; 23(1):1-84. PubMed ID: 30618357
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Colonoscopy Outreach vs Fecal Immunochemical Test Outreach on Colorectal Cancer Screening Completion: A Randomized Clinical Trial.
    Singal AG; Gupta S; Skinner CS; Ahn C; Santini NO; Agrawal D; Mayorga CA; Murphy C; Tiro JA; McCallister K; Sanders JM; Bishop WP; Loewen AC; Halm EA
    JAMA; 2017 Sep; 318(9):806-815. PubMed ID: 28873161
    [TBL] [Abstract][Full Text] [Related]  

  • 10. "Finding the Right FIT": Rural Patient Preferences for Fecal Immunochemical Test (FIT) Characteristics.
    Pham R; Cross S; Fernandez B; Corson K; Dillon K; Yackley C; Davis MM
    J Am Board Fam Med; 2017; 30(5):632-644. PubMed ID: 28923816
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gender-specific cut-off levels in colorectal cancer screening with fecal immunochemical test: A population-based study of colonoscopy findings and costs.
    Ribbing Wilén H; Saraste D; Blom J
    J Med Screen; 2021 Dec; 28(4):439-447. PubMed ID: 34106777
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Individual and Geospatial Characteristics Associated With Use and Nonuse of the Fecal Immunochemical Test (FIT) for Colorectal Cancer Screening in an Urban Minority Population.
    Ramai D; Etienne D; Ayide G; Fields PJ; Reddy M
    J Clin Gastroenterol; 2019; 53(10):744-749. PubMed ID: 30222644
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The multitarget fecal immunochemical test versus the fecal immunochemical test for programmatic colorectal cancer screening: a cross-sectional intervention study with paired design.
    Wisse PHA; de Klaver W; van Wifferen F; Meiqari L; Bierkens M; Greuter MJE; Carvalho B; van Leerdam ME; Spaander MCW; Dekker E; Coupé VMH; de Wit M; Meijer GA
    BMC Cancer; 2022 Dec; 22(1):1299. PubMed ID: 36503495
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative effectiveness of fecal immunochemical test outreach, colonoscopy outreach, and usual care for boosting colorectal cancer screening among the underserved: a randomized clinical trial.
    Gupta S; Halm EA; Rockey DC; Hammons M; Koch M; Carter E; Valdez L; Tong L; Ahn C; Kashner M; Argenbright K; Tiro J; Geng Z; Pruitt S; Skinner CS
    JAMA Intern Med; 2013 Oct; 173(18):1725-32. PubMed ID: 23921906
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interval cancers in a population-based screening program for colorectal cancer with gender-specific cut-off levels for fecal immunochemical test.
    Ribbing Wilén H; Saraste D; Blom J
    J Med Screen; 2022 Sep; 29(3):156-165. PubMed ID: 35257615
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disparities in Colorectal Cancer Screening Practices in a Midwest Urban Safety-Net Healthcare System.
    Elangovan A; Skeans J; Lalani I; Ullah F; Roy A; Kaelber DC; Cooper GS; Sandhu DS
    Dig Dis Sci; 2021 Aug; 66(8):2585-2594. PubMed ID: 32816217
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association Between Primary Care Visits and Colorectal Cancer Screening Outcomes in the Era of Population Health Outreach.
    Halm EA; Beaber EF; McLerran D; Chubak J; Corley DA; Rutter CM; Doubeni CA; Haas JS; Balasubramanian BA
    J Gen Intern Med; 2016 Oct; 31(10):1190-7. PubMed ID: 27279097
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of colorectal cancer screening participation in remote northern Canada: A retrospective cohort study.
    Smith HA; Scarffe AD; Brunet N; Champion C; Kandola K; Tessier A; Boushey R; Kuziemsky C
    World J Gastroenterol; 2020 Dec; 26(48):7652-7663. PubMed ID: 33505142
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factors associated with interval colorectal cancer after negative FIT: Results of two screening rounds in the Dutch FIT-based CRC screening program.
    Breekveldt ECH; Toes-Zoutendijk E; van de Schootbrugge-Vandermeer HJ; de Jonge L; Kooyker AI; Spaander MCW; van Vuuren AJ; van Kemenade FJ; Ramakers C; Dekker E; Nagtegaal ID; van Leerdam ME; Lansdorp-Vogelaar I
    Int J Cancer; 2023 Apr; 152(8):1536-1546. PubMed ID: 36444504
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adding family history to faecal immunochemical testing increases the detection of advanced neoplasia in a colorectal cancer screening programme.
    Kallenberg FG; Vleugels JL; de Wijkerslooth TR; Stegeman I; Stoop EM; van Leerdam ME; Kuipers EJ; Bossuyt PM; Dekker E
    Aliment Pharmacol Ther; 2016 Jul; 44(1):88-96. PubMed ID: 27170502
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.